US6485900B1 - Synthetic antigen for the detection of AIDS-related disease - Google Patents

Synthetic antigen for the detection of AIDS-related disease Download PDF

Info

Publication number
US6485900B1
US6485900B1 US07/541,163 US54116390A US6485900B1 US 6485900 B1 US6485900 B1 US 6485900B1 US 54116390 A US54116390 A US 54116390A US 6485900 B1 US6485900 B1 US 6485900B1
Authority
US
United States
Prior art keywords
peptide
lav
htlv
iii
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/541,163
Inventor
Wesley Loren Cosand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Rad Laboratories Inc
Original Assignee
Bio Rad Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US6485900(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/767,303 external-priority patent/US4629783A/en
Application filed by Bio Rad Laboratories Inc filed Critical Bio Rad Laboratories Inc
Priority to US07/541,163 priority Critical patent/US6485900B1/en
Priority to US08/245,516 priority patent/US6130314A/en
Priority to US08/252,987 priority patent/US6214539B1/en
Application granted granted Critical
Priority to US10/305,271 priority patent/US20030211117A1/en
Publication of US6485900B1 publication Critical patent/US6485900B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Definitions

  • lymphadenopathy syndrome and acquired immune deficiency disease are caused by an infectious retrovirus designated lymphadenopathy virus (LAV), human T-cell lymphotropic virus-III (HTLV-III), AIDS-related virus (ARV), or immune deficiency-associated virus (IDAV)
  • LAV lymphadenopathy virus
  • HTLV-III human T-cell lymphotropic virus-III
  • ARV AIDS-related virus
  • IDAV immune deficiency-associated virus
  • Hopp and Woods Proc. Natl. Acad. Sci. USA (1981) 78:3824, describe criteria for selecting peptides as potential epitopes of polypeptides based on their relative hydrophilicity. In one study employing these criteria, a 12-amino acid peptide was synthesized that bound 9% of antibodies elicited by the native protein (Hopp, Molec. Immunol . (1981) 18:869). In general, Hopp/Woods criteria have been shown not to have a high predictive value. Furthermore, epitopes have been demonstrated which are not hydrophilic (Kazim et al., Biochem. J . (1982) 203:201).
  • Peptide sequences capable of immunologically mimicking proteins encoded in the gag and/or env regions of the LAV/HTLV-III retrovirus are provided as reagents for use in the screening of blood and blood products for prior exposure to the retrovirus.
  • the peptides are of at least 5 amino acids and can be used in various specific binding assays for the detection of antibodies to LAV/HTLV-III virus, for the detection of LAV/HTLV-III antigens, or as immunogens.
  • a virus is considered to be the same as or equivalent to LAV/HTLV-III if it substantially fulfills the following criteria:
  • the virus is tropic for T-lymphocytes, especially T-helper cells (CD4 + , according to the international nomenclature defined in Bernard et al., eds. Leucocyte Typing , New York: Springer Verlag, 1984);
  • the virus is cytopathic for infected CD4 + cells (rather than transforming, as are HTLV-I and -II);
  • the virus encodes an RNA-dependent DNA polymerase (reverse transcriptase) which is Mg 2+ -dependent (optimum concentration 5 mM), has a pH optimum of 7.8, is not inhibitable by actinomycin D, and can employ oligo(dT) 12-18 as a primer for reverse transcription from its 3′ LTR;
  • reverse transcriptase reverse transcriptase
  • the virus can be labeled with [ 3 H]-uridine;
  • the virus is substantially cross-reactive immunologically with the proteins encoded by the gag and env regions of LAV/HTLV-III;
  • the virus shares substantial nucleotide homology (approximately 75-100%) and amino acid sequence homology (approximately 75-100%) with LAV or HTLV-III.
  • Novel peptides are provided which immunologically mimic proteins encoded by the LAV/HTLV-III retrovirus, particularly proteins encoded by the gag and/or env regions of the viral genome. To accommodate strain-to-strain variations among different isolates, adjustments for conservative substitutions and selection among the alternatives where non-conservative substitutions are involved, may be made. These peptides can be used individually or together for detection of the virus or of antibodies to the virus in a physiological sample. Depending upon the nature of the test protocol, the peptides may be labeled or unlabeled, bound to a solid surface, conjugated to a carrier or other compounds, or the like.
  • the peptides of interest will be derived from the peptides encoded by the gag region or the env region. These peptides will be primarily derived from p55 or fragments thereof, e.g., p25 and p18, or gp150 and fragments thereof, e.g., gp41. These peptides will be given Roman numerals, but will also be given numerical designations which are arbitrarily associated with the manner in which they were produced.
  • the coding regions extending from about base pair (bp) 450 to bp 731, particularly from about bp 450 to bp 545 (97) and bp 696 to bp 731 (71); from about bp 900 to bp 1421, particularly from about bp 921 to bp 1016, including bp 921 to bp 1010; bp 972 to bp 1016 (92); and bp 936 to bp 995 (17); or from about bp 1158 to about bp 1400, particularly bp 1164 to bp 1250 (90); bp 1278 to bp 1385 (88); and bp 1320 to bp 1385 (15), of the LAV/HTLV-III retrovirus. (Numbering according to Wain-Hobson-et al., supra.)
  • the regions of particular interest will be those polypeptides encoded within the bp 7210 to bp 7815 regions, particularly within bp 7231 to bp 7794, more particularly within about bp 7246 through bp 7317 (36), bp 7516 through bp 7593 (39), particularly bp 7543 through bp 7593 (79) and bp 7561 through 7593 (78), bp 7708 through bp 7779 (23), bp 7630 through bp 7689 (40), bp 7498 through bp 7554 (56).
  • the peptides of interest will include at least five, sometimes six, sometimes eight, sometimes 12, usually fewer than about 50, more usually fewer than about 35, and preferably fewer than about 25 amino acids included within a sequence coded for by the LAV/HTLV-III retrovirus. in each instance, desirably the oligopeptide will be as small as possible, while still maintaining substantially all of the sensitivity of the larger peptide. In some instances it may be desirable to join two or more oligopeptides which are non-overlapping in the same peptide structure or as individual peptides, which separately or together provide equivalent sensitivity to the parent.
  • the peptides may be modified by introducing conservative or non-conservative substitutions in the peptides, usually fewer than 20 number percent, more usually fewer than 10 number percent of the peptides being exchanged. In those situations where regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the differing epitopes of the different retroviral strains. In many instances to provide chemical and physical stability, methionine may be replaced by norleucine (Nor).
  • the polypeptides employed in the subject invention need not be identical to any particular LAV/HTLV-III polypeptide sequence, so long as the subject compounds are able to provide for immunological competition with proteins of at least one of the strains of the LAV/HTLV-III retrovirus. Therefore, the subject polypeptides may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use. By conservative substitutions is intended combinations such as gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr.
  • the sequence will not differ by more than twenty percent from the sequence of at least one strain of an LAV/HTLV-III retrovirus except where additional amino acids may be added at either terminus for the purpose of providing an “arm” by which the peptides of this invention may be conveniently immobilized.
  • the arms will usually be at least 1 amino acid and may be 50 or more amino acids, more often 1 to 10 amino acids.
  • one or two amino acids may be added to the termini of an oligopeptide or peptide to provide for ease of linking of peptides one to another, for coupling to a support or larger peptide, for reasons to be discussed subsequently, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like.
  • Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, may be introduced at the C- or N-terminus of the peptide or oligopeptide to provide for a useful functionality for linking.
  • cysteines Of particular interest is the presence of from 1 to 3 cysteines at the C- or N-terminus for linking to a support.
  • the cysteine could be linked through a disulfide linkage to a dithio- or thio-functionalized support on a thioether linkage to an activated olefin support.
  • the peptide or oligopeptide sequences may differ from the natural sequence by the sequence being modified by terminal-NH 2 acylation, e.g., acetylation, or thioglycolic acid amidation, terminal-carboxy amidation, e.g., ammonia, methylamine, etc. In some instances, these modifications may provide sites for linking to a support or other molecule.
  • terminal-NH 2 acylation e.g., acetylation, or thioglycolic acid amidation
  • terminal-carboxy amidation e.g., ammonia, methylamine, etc.
  • these modifications may provide sites for linking to a support or other molecule.
  • the peptides and oligopeptides of interest will now be considered.
  • the first peptides of interest will be derived from the gag region, particularly the protein referred to as p25 and p18.
  • the peptides for p25 are as follows:
  • the peptide I (15) encoded in the region bp 1320 to bp 1385 will have the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • amino terminal Y e.g., Tyr or Cys, if present, is added to facilitate coupling of the peptide to a protein carrier.
  • next peptide II (17) will be encoded by the region extending from about bp 936 to bp 995 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • amino terminal Y has been defined previously.
  • X and Y have been defined previously and Z is a bond, an amino acid which provides a means of linking, e.g., cysteine, tyrosine, etc., or taken together with X provides a functional group which may be used for linking, e.g., an olefin as in allyl or maleimidyl, dithio, etc.
  • next peptide of interest, III (92) will be encoded by the region extending from about bp 972 to bp 1016 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • this peptide will have no more than about 15 amino acids encoded by the LAV/HTLV III genome.
  • next peptide, IV (90) will be encoded by the region extending from about bp 1164 to bp 1250 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • this peptide will have no more than about 29 amino acids encoded by the LAV/HTLV III genome.
  • the peptide, V (88) will be encoded by the region extending from about bp 1278 to bp 1385 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • next peptides of interest will be derived from the gag protein region referred to as p18.
  • next peptide of interest, VI (97) will be encoded by the region extending from about bp 450 through bp 545 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • the next peptide of interest VII (71) will be encoded by the region extending from about bp 696 to bp 731.
  • This peptide will include any oligopeptides coding for linear epitopes with the following amino acid sequence:
  • polypeptides of interest will be those derived from the env region, from gp110 (110 kDal).
  • next peptide of interest, VIII will be encoded by the region extending from about bp 7246 through bp 7317 and while coming within the general limitations indicated previously, will preferably have no more than 24 amino acids encoded by the LAV/HTLV III genome.
  • the peptide of interest will generally have the following amino acid sequence, where oligopeptides included within the following sequence will include, linear epitopes within such sequence:
  • carboxy terminal Z e.g., Cys, if present, is an amino acid added to facilitate coupling of the peptide to a protein carrier.
  • Oligopeptides contained within the above sequence of particular interest include:
  • next peptides of interest will be derived from the env region known as gp41.
  • the next peptide, IX (56), will be encoded by the region extending from about bp 7498 to bp 7554, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • Oligopeptides contained within the above sequence of particular interest include:
  • next peptide of interest, X (39), will be encoded by the region from about bp 7516 through bp 7593 and has the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • next peptide, XI (40), will be encoded by the region extending from about bp 7630 to 7689 where oligopeptides included within the following sequence will include linear epitopes within such sequence:
  • the next peptide of interest, XII (23), will be encoded by the region extending from about bp 7708 through bp 7779.
  • This peptide will include any oligopeptides coding for linear epitopes within the following amino acid sequence:
  • the next peptide of interest, XIII (79), will be encoded by the region extending from about bp 7543 through bp 7593.
  • This peptide will include any oligopeptides coding for linear epitopes within the following amino acid sequence:
  • the next peptide of interest, XIIIa (78), will be encoded by the region extending from about bp 7561 through bp 7593.
  • This peptide will include any oligopeptide coding for linear epitopes within the following amino acid sequence:
  • the mercaptan group of cysteines or thioglycolic acids used for acylating terminal amino groups or the like for linking two of the peptides or oligopeptides or combinations thereof by a disulfide linkage or a longer linkage.
  • compounds may be employed having bis-haloacetyl groups, nitroarylhalides, or the like, where the reagents are specific for thio groups.
  • the linking between the two mercapto groups of the different peptides or oligopeptides may be a single bond or a linking group of at least two, usually at least four, and not more than about 16, usually not more than about 14 carbon atoms.
  • a member of a sequence from the gag region is linked to a member from the env region.
  • chimeric peptides which may include non-amino acid linkages, may be further modified as will be described for the peptides and oligopeptides.
  • the subject peptides may be employed linked to a soluble macromolecular (e.g., ⁇ 5 kDal) carrier.
  • the carrier may be a poly(amino acid), either naturally occurring or synthetic, to which antibodies are unlikely to be encountered in human serum.
  • Illustrative polypeptides include poly-L-lysine, bovine serum albumin, keyhole limpet hemocyanin, bovine gamma globulin, etc. The choice is primarily one of convenience and availability.
  • conjugates there will be at least one molecule of at least one subject peptide per macromolecule and not more than about 1 per 0.5 kDal, usually not more than about 1 per 2 kDal of the macromolecule.
  • One or more different peptides may be linked to the same macromolecule.
  • the manner of linking is conventional, employing such reagents as p-maleimidobenzoic acid, p-methyldithiobenzoic acid, maleic acid anhydride, succinic acid anhydride, glutaraldehyde, etc.
  • the linkage may occur at the N-terminus, C-terminus or at a site intermediate the ends of the molecule.
  • the subject peptide may be derivatized for linking, may be linked while bound to a support, or the like.
  • the compounds may be employed as labeled or unlabeled compounds depending upon their use.
  • label is intended a molecule which provides, directly or indirectly, a detectable signal.
  • Various labels may be employed, such as radionuclides, enzymes, fluorescers, chemiluminescers, enzyme substrates, cofactors or inhibitors, particles, e.g., magnetic particles, combinations of ligands and receptors, e.g., biotin and avidin, or the like.
  • the peptides may be modified in a variety of ways for binding to a surface, e.g., microtiter plate, glass beads, chromatographic surface, e.g., paper, cellulose, silica gel, or the like.
  • the particular manner in which the polypeptides are joined to another compound or surface is conventional and finds ample illustration in the literature. See, for example, U.S. Pat. Nos. 4,371,515; 4,487,715; and patents cited therein.
  • Various assay protocols may be employed for detecting the presence of either antibodies to retroviral proteins or retroviral proteins themselves.
  • the labeled reagent where the label allows for a detectable signal, or binding the peptide, either directly or indirectly to a surface, where antibody to the peptide in the sample will become bound to the peptide on the surface.
  • the presence of human antibody bound to the peptide can then be detected by employing a xenogeneic antibody specific for human immuno-globulin, normally both human IgM and IgG, or a labeled protein specific for immune complexes, e.g., Rf factor or S. aureus protein A.
  • Peptide may be bound to a surface or support (“support”) and labeled antibody allowed to compete with antibody in the sample for the limited amount of bound peptide.
  • the amount of label bound to the support would be related to the amount of competitive antibody in the sample.
  • Antibody could be bound to the support and the sample combined with labeled peptide. After contact of the reaction mixture with the bound antibody, the amount of label bound to the support would relate to the amount of cognate antibody in the sample.
  • Xenogeneic anti-human antibody e.g., antibodies to the F C of IgG and IgM (immunoglobulins)
  • the sample would be contacted with the immunoglobulins and labeled peptide, whereby the amount of labeled peptide bound to the support would be indicative of the presence of the cognate antibodies.
  • homogeneous assays can be employed where the peptide is bound to an enzyme, fluorescer, or other label, where the binding of antibody to the peptide results in being able to discriminate between the label involved with a specific binding pair complex and label which is not involved in the complex.
  • assays involving such techniques see for example U.S. Pat. Nos. 3,817,837; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876, whose disclosures are incorporated herein by reference.
  • the subject peptides may be conjugated to a fluorescent molecule, such as fluorescein, rhodamine or umbelliferone.
  • a fluorescent molecule such as fluorescein, rhodamine or umbelliferone.
  • Various techniques may be used for detecting complex formation with antibodies, e.g., fluorescence polarization. In this assay the fluorescence polarization is different between complexed and uncomplexed peptide conjugate. Apparatuses are available for measuring changes in fluorescence polarization, e.g., TDx supplied by Abbott Laboratories, Chicago, Ill.
  • sample containers e.g., microtiter plate wells
  • the subject polypeptides or conjugates thereof are adhered to the container bottom and/or walls either covalently or non-covalently.
  • the sample normally human blood or serum diluted in an appropriately buffered medium, is added to the container and a sufficient time allowed for complex formation between the polypeptide(s) and any cognate antibodies in the sample. The supernatant is removed and the container washed to remove non-specifically bound proteins.
  • a labeled specific binding protein which specifically binds to the complex is employed for detection.
  • To the container may be added xenogeneic antisera to human immunoglobulin, particularly anti-(human IgM and IgG) in an appropriately buffered medium.
  • the xenogeneic antisera will normally be labeled with a detectable label, e.g., radionuclide or enzyme.
  • proteins specific for the immune complex may be employed, e.g., S. aureus protein A.
  • the label may then be detected.
  • a developer solution is added.
  • the developer solution will contain an enzyme substrate and possibly enzyme cofactors, chromogens, etc., which, upon reaction, provide a colored or fluorescent product which may be detected calorimetrically or fluorimetrically, respectively.
  • the peptides can be prepared in a wide variety of ways.
  • the peptides because of their relatively short size, may be synthesized in solution or on a solid support in accordance with conventional techniques.
  • Various automatic synthesizers are commercially available today and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Co., 1984; and Tam et al., J. Am. Chem. Soc . (1983) 105:6442.
  • hybrid DNA technology may be employed where a synthetic gene may be prepared by employing single strands which code for the polypeptide or substantially complementary strands thereof, where the single strands overlap and can be brought together in an annealing medium so as to hybridize. The hybridized strands may then be ligated to form the complete gene and by choice of appropriate termini, the gene may be inserted into expression vectors, which are readily available today. See, for example, Maniatis et al., Molecular Cloning, A Laboratory Manual, CSH, Cold Spring Harbor Laboratory, 1982. Or, the region of the viral genome coding for the peptide may be cloned by conventional recombinant DNA techniques and expressed (see Maniatis, supra).
  • DNA coding sequences which may be used for expressing peptides I-XIII are:
  • Fragments from these sequences may be employed for expression of peptide fragments, conservative base changes can be made, where the modified codon(s) code for the same amino acid(s), or non-conservative changes in the coding sequence may be made, where the resulting amino acid may be a conservative or non-conservative change.
  • the coding sequence may be extended at either the 5′- or 3′-terminus or both termini to extend the peptide, while retaining its epitopic site.
  • the extension may provide for an arm for linking, e.g., to a label, such as an enzyme, for joining two or all of the peptides together in the same chain, for providing antigenic activity, or the like.
  • the coding sequence will be provided with start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in a cellular host, e.g., prokaryotic or eukaryotic, bacterial, yeast, mammal, etc.
  • a cellular host e.g., prokaryotic or eukaryotic, bacterial, yeast, mammal, etc.
  • sequences by themselves, fragments thereof, or larger sequences, usually at least 15 bases, preferably at least 18 bases, may be used as probes for detection of retroviral RNA or proviral DNA.
  • Numerous techniques are described, such as the Grunstein-Hogness technique, Southern technique, Northern technique, dot-blot, improvements thereon, as well as other methodology. See, for example, WO 83/02277 and Berent et al., Biotechniques (1985) 3:208.
  • the polypeptides may be prepared as fused proteins, where the polypeptide may be the N- or C-terminus of the fused polypeptide.
  • the resulting fused protein could be used directly by itself as the reagent or the subject polypeptide may be cleaved from all or a portion of the remaining sequence of the fused protein.
  • the polypeptide may be cleaved employing cyanogen bromide.
  • proteolytic cleavage site e.g., poly-lysine and/or -arginine or combinations thereof, or the internal methionine could be substituted with an amino acid such as leucine and an N-terminal methionine added for cyanogen bromide cleavage.
  • a wide variety of proteases, including dipeptidases, are well known and the appropriate processing signal could be introduced at the proper site. The processing signal may have tandem repeats so as to insure cleavage, since the presence of one or more extraneous amino acids will not interfere with the utility of the subject polypeptides.
  • the physiological sample e.g., saliva, blood, plasma, or serum
  • an assay medium which will usually be an aqueous buffered medium employing one of a variety of buffers, such as phosphate, tris, or the like.
  • a preferred diluent is blotto (5% w/v nonfat dry milk, 0.01% thimerosal, 0.01% Antifoam A in 0.01 M sodium phosphate, pH 7.2, and 0.15 M NaCl).
  • the pH will be in the range of about 6 to 9.
  • the sample will then be combined with the reagent in accordance with the appropriate protocol and sufficient time allowed for binding. Where a heterogeneous system is used, usually the stages will be followed by washes, to minimize non-specific binding. At the end of the procedure, the label will be detected in accordance with conventional ways.
  • the subject peptides may also find use by themselves or in combination in vaccines.
  • the peptides may be formulated in a convenient manner, generally at concentrations in the range of 1 ⁇ g to 20 mg/kg of host.
  • Physiologically acceptable media may be used as carriers, such as sterile water, saline, phosphate buffered saline, and the like.
  • Adjuvants may be employed, such as aluminum hydroxide gel, or the like.
  • Administration may be by injection, e.g., intramuscularly, peritoneally, subcutaneously, intravenously, etc. Administration may be one or a plurality of times, usually at one to four week intervals.
  • Peptides 15, 71, 88, 90, 92 and 97 were assembled on a t-butyloxycarbonyl (BOC)-methylbenzyl-cysteine-phenyl-acetamidomethyl (PAM) polystyrene/divinylbenzene resin (Applied Biosystems, Inc., Foster City, Calif.).
  • PAM t-butyloxycarbonyl
  • PAM methylbenzyl-cysteine-phenyl-acetamidomethyl
  • Benzyl based side chain protection and BOC alpha-amine protection were used. Tryptophan was protected by the formyl moiety, methionine was protected by its sulfoxide, and dinitrophenol was used for protecting histidine. Protecting groups were removed by conventional procedures.
  • Peptide 36 was assembled on a benzhydrylamine polystyrene/divinylbenzene resin in a Beckman 990 peptide synthesizer (Beckman Instruments, La Brea, Calif.). Benzyl based side chain protection and BOC alpha-amine protection were used. All the residues were added by the direct dicyclohexylcarbodiimide method, except for glutamine which was coupled as the hydroxybenzotriazole ester.
  • Peptide 39 was synthesized on a benzhydryl-amine resin as described for peptide 36 with asparagine also being coupled as the ester.
  • the peptides were deprotected and cleaved from the resin by the Tam “low-high” HF protocol (Tam et al., supra).
  • Peptides 36, 39, 79, 78, 88, 90, 92 and 97 were extracted from the resin in 5% acetic acid and subjected to gel filtration chromatography in 5% acetic acid.
  • Peptides 15 and 71 were extracted in 0.5M ammonium carbonate/0.001M dithiothreitol (DTT) and chromatographed in 0.05M ammonium carbonate/0.005M ⁇ -mercaptoethanol. Fractions containing the peptide were pooled and lyophilized. The integrity of the synthetic products was assured by ninhydrin monitoring after each coupling and by analytical reverse phase chromatography and amino acid analysis.
  • Peptides 90, 92 and 97 were polymerized by oxidation of their sulfhydryls to intermolecular disulfides. Briefly, the lyophilized reduced peptide was dissolved in minimal 6M guanidine HCl/0.1M sodium phosphate, pH 9.0, and allowed to oxidize overnight at room temperature.
  • Peptides 15, 23, 36, 40, 49, 50 and 56 synthesized above were conjugated to bovine serum albumin (BSA) which had been derivatized with N-succinimidyl-4 -(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), essentially as described by Ishikawa et al., J. of Immunoassay (1983) 4:209.
  • BSA bovine serum albumin
  • SMCC N-succinimidyl-4 -(N-maleimidomethyl)-cyclohexane-1-carboxylate
  • the peptides synthesized above were dissolved in 0.1M sodium phosphate, pH 8.0 to a concentration of 5 mg/ml (peptide 36), 8 mg/ml (peptide 15) or 1.6 mg/ml (peptide 39). To 1.5 ml of each solution was added 2 mg of solid DTT. The solutions were stirred for 30 min at 30° C., after which they were subjected to gel filtration chromatography on Sephadex G-10, equilibrated in 0.1M potassium phosphate, pH 6.0. The tritium-containing fractions, as determined by scintillography of aliquots, were pooled and mixed with 1 ml (0.5 ml for peptide V) of SMCC-derivatized BSA. The resultant mixtures were stirred at 30° C. for 12 hr and then dialyzed exhaustively against water.
  • the other peptides were prepared in accordance with the procedures described above and conjugated to BSA in accordance with the above described procedures.
  • the ratio of peptide to BSA was determined by employing radiotracers in accordance with conventional ways.
  • the lyophilized peptide or protein/peptide conjugate was dissolved in 6M guanidine HCl.
  • the guanidine solutions were diluted in 0.05M carbonate/bicarbonate buffer (pH 9.6) to a final peptide concentration of 8 to 40 ⁇ g/ml just prior to plating in the 96-well plates.
  • Fifty ⁇ l of peptide solution were aliquoted per microtiter well and incubated at 4° C. overnight. Plates were then blocked with BLOTTO (5% [w/v] nonfat dry milk/0.01% thimerosal/0.01% antifoam A in 0.01M sodium phosphate, pH 7.2/0.15M sodium chloride) for one hour at 37° C.
  • BLOTTO 5% [w/v] nonfat dry milk/0.01% thimerosal/0.01% antifoam A in 0.01M sodium phosphate, pH 7.2/0.15M sodium chloride
  • Sera were diluted 1:100 with a 1:1 mixture of BLOTTO and PBS (0.01M sodium phosphate, pH 7.3/0.15M NaCl), and 50 ⁇ l of diluted sera was added to each well and incubated for one hour at 37° C. The sera were removed and the plates were washed three times in wash buffer (0.15M NaCl/0.05% [w/v] Tween 20) before adding 100 ⁇ l of the goat anti-human IgG/horseradish peroxidase conjugate (50% stock diluted 1:10,000 in 50 mM sodium citrate/0.05% Tween 20/1% heat-inactivated normal goat serum; obtained from Antibodies, Inc., Davis, Calif.) for one hour at 37° C.
  • wash buffer 0.15M NaCl/0.05% [w/v] Tween 20
  • the conjugate was removed and the plates washed three times with 0.15M NaCl/0.05% (w/v) Tween 20.
  • the ELISA was developed by adding 100 ⁇ l per well of substrate solution (10 mg 3,3′,5,5′-tetramethylbenzidine in 50 ml 0.05M sodium citrate, pH 7.0) for 30 min at room temperature. Reactions were stopped with 100 ⁇ l per well of 3N H 2 SO 4 , and the optical density at 450 nm determined by an automated ELISA reader.
  • Table 1 gives ELISA results for all petpides that are immunoreactive.
  • Peptides 49 and 50 are part of peptide 36.
  • Peptide 56 partially overlaps peptide 39.
  • Peptide 49-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
  • Peptide 50-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
  • Peptide 56-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
  • Peptide 40-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
  • Peptide 23-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
  • Peptide 15-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
  • Peptide 36-BSA reactive with 9/10 positive sera; not reactive with 2/2 negative sera.
  • peptide 56 which partially overlaps peptide 39, is not reactive with all sera that are reactive with peptide 39. This suggests that there are at least two reactive epitopes within peptide 39 or that peptides 39 and 56 contain non overlapping reactive epitopes.
  • Peptide 23 (both conjugated to BSA and unconjugated) was further tested against a larger panel of sera (23 positives, 8 negatives) and displays a sensitivity of 80-90%.
  • Table 2 shows that two of the peptides derived from the gag region (#15 and #17) are reactive with LAV seropositive sera that are poorly reactive or unreactive with peptide 39. This supports the use of a combination of gag and env peptides to produce a more sensitive assay.
  • Table 3 compares results obtained with peptides 15-BSA and 39 with results obtained with these peptides physically mixed (15-BSA+39) or chemically combined (thiol-oxidized 15+39).
  • Table 4 compares results obtained with peptides 71, 78, 79, 88, 90, 92 and 97 in an ELISA assay. All of the peptides except one provide better than 70% correlation for positives and two peptides had 100% correlation.
  • homosexual 121 LAS and/or 1.483 yes 0.09 1.51 >2.0 1.96 homosexual 122 LAS and/or 1.283 yes 0.14 1.88 >2.0 2.33 homosexual 124 LAS and/or 1.189 yes 0.60 1.06 n.d. n.d. homosexual 125 LAS and/or 1.232 yes 0.18 1.53 n.d. n.d. homosexual 126 LAS and/or 1.233 yes 0.24 0.51 >2 1.5 homosexual 127 LAS and/or 1.046 yes 0.25 1.52 n.d. n.d. homosexual 128 LAS and/or 1.284 yes 0.09 1.07 n.d. n.d. homosexual 129 LAS and/or 1.081 yes 0.33 0.42 n.d. n.d.
  • Radiolabeled LAV antigens were disrupted in RIPA buffer (Gilead et al., Nature (1976) 264:263) and then were reacted with human serum.
  • the resultant immune complexes were separated by binding to a Staphylococcus aureus adsorbent (Kessler, J. Immunology (1975) 115:1617) followed by multiple washings.
  • Immuneprecipitated antigens were analyzed by SDS polyacrylamide gel electrophoresis (Laemmli, Nature (1970) 227:680) followed by fluorography. Presence of either a p25 or gp43 band was considered necessary and sufficient to confirm a sample as seropositive.
  • peptides of the subject invention by employing one or a combination of peptides of the subject invention, a sensitive accurate test for the presence of antibodies to AIDS is provided.
  • the subject peptides can be used by themselves or in combination with a screening assay or confirmatory assay, where the complete lysate or complete antigens may be employed as an independent procedure.
  • a screening assay or confirmatory assay where the complete lysate or complete antigens may be employed as an independent procedure.
  • DNA sequences coding for the peptides would also find similar specificity in a DNA hybridization assay.
  • the subject invention allows for the detection of patients who have been exposed to the retroviral etiologic agent of lymphadenopathy syndrome and/or AIDS.

Abstract

Novel peptides are provided having substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides in screening blood products.

Description

This application is a continuation of application Ser. No. 06/844,485, filed Mar. 26, 1986 now abandoned, which is a continuation-in-part of application Ser. No. 06/767,303, filed Aug. 19, 1985 now abandoned, which is a continuation-in-part of application Ser. No. 06/728,052, filed Apr. 29, 1985 now abandoned, which disclosures are incorporated herein by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
With the discovery that the diseases called lymphadenopathy syndrome and acquired immune deficiency disease (AIDS) are caused by an infectious retrovirus designated lymphadenopathy virus (LAV), human T-cell lymphotropic virus-III (HTLV-III), AIDS-related virus (ARV), or immune deficiency-associated virus (IDAV), there has become an immediate need to be able to detect potential vectors of the disease, such as blood from diseased individuals, which may be employed for transfusions or from which specific blood factors may be isolated.
To detect potential vectors of the disease, it is necessary to have viral proteins and/or antibodies to such proteins. Because of the hazards associated with growing the LAV/HTLV-III retrovirus, there is significant interest in establishing means for obtaining the viral proteins or their immunologic equivalents, which means do not necessitate handling large volumes of live, potentially infectious virus. In choosing alternatives, one must be concerned with the fact that the viruses have been reported to be highly polymorphic, frequently changing as the retrovirus is passaged.
2. Brief Description of the Relevant Literature
The various antigens of the retrovirus are described by Saxinger et al., Science (1985) 227:1036-1038. See also Gallo et al., ibid. (1984) 224:500; Sarangadharn et al., ibid. 224:506; Barre-Sinoussi et al., ibid. (1983) 220:868; Montagnier et al., in Human T-Cell Leukemia/Lymphoma Virus, Gallo, Essex, Gross, eds. (Cold Spring Harbor laboratory, Cold Spring Harbor, N.Y.), 1984, p. 363. These may include, but are not limited to, p13, p18, p25, p36, gp43, p55, gp65, gp110, etc., where the numbers may differ depending upon the reporter.
Hopp and Woods, Proc. Natl. Acad. Sci. USA (1981) 78:3824, describe criteria for selecting peptides as potential epitopes of polypeptides based on their relative hydrophilicity. In one study employing these criteria, a 12-amino acid peptide was synthesized that bound 9% of antibodies elicited by the native protein (Hopp, Molec. Immunol. (1981) 18:869). In general, Hopp/Woods criteria have been shown not to have a high predictive value. Furthermore, epitopes have been demonstrated which are not hydrophilic (Kazim et al., Biochem. J. (1982) 203:201). Other studies of polypeptide antigenicity include Green et al., Cell (1982) 28:477, where peptides were employed which elicited antibodies, which antibodies were capable of binding to the native protein, while conversely antibodies which were elicited by the native protein failed to bind to the peptides; and Trainer et al., Nature (1984) 312:127, whose results with myohaemerythrin paralleled those of Green et al.
The complete nucleotide sequence of LAV is reported by Wain-Hobson et al., Cell (1985) 40:9. The complete sequence for HTLV-III is reported by Muesing et al., Nature (1985) 313:450, while the complete sequence for ARV is reported by Sanchez-Pescador et al., Science (1985) 227:484. All three viruses exhibit substantial nucleotide homology and are similar with respect to morphology, cytopathology, requirements for optimum reverse transcriptase activity, and at least some antigenic properties (Levy et al., Science (1984) 225:840; Shupbach et al., Science (1984) 224:503), and hence should be considered isolates of the same virus. See also, Chang et al., Science (1985) 228:93.
SUMMARY OF THE INVENTION
Peptide sequences capable of immunologically mimicking proteins encoded in the gag and/or env regions of the LAV/HTLV-III retrovirus are provided as reagents for use in the screening of blood and blood products for prior exposure to the retrovirus. The peptides are of at least 5 amino acids and can be used in various specific binding assays for the detection of antibodies to LAV/HTLV-III virus, for the detection of LAV/HTLV-III antigens, or as immunogens.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
For the purpose of this disclosure, a virus is considered to be the same as or equivalent to LAV/HTLV-III if it substantially fulfills the following criteria:
(a) The virus is tropic for T-lymphocytes, especially T-helper cells (CD4+, according to the international nomenclature defined in Bernard et al., eds. Leucocyte Typing, New York: Springer Verlag, 1984);
(b) The virus is cytopathic for infected CD4+ cells (rather than transforming, as are HTLV-I and -II);
(c) The virus encodes an RNA-dependent DNA polymerase (reverse transcriptase) which is Mg2+-dependent (optimum concentration 5 mM), has a pH optimum of 7.8, is not inhibitable by actinomycin D, and can employ oligo(dT)12-18 as a primer for reverse transcription from its 3′ LTR;
(d) The virus bands in a sucrose gradient at a density of approximately 1.16;
(e) The virus can be labeled with [3H]-uridine;
(f) The virus is substantially cross-reactive immunologically with the proteins encoded by the gag and env regions of LAV/HTLV-III; and
(g) The virus shares substantial nucleotide homology (approximately 75-100%) and amino acid sequence homology (approximately 75-100%) with LAV or HTLV-III.
Novel peptides are provided which immunologically mimic proteins encoded by the LAV/HTLV-III retrovirus, particularly proteins encoded by the gag and/or env regions of the viral genome. To accommodate strain-to-strain variations among different isolates, adjustments for conservative substitutions and selection among the alternatives where non-conservative substitutions are involved, may be made. These peptides can be used individually or together for detection of the virus or of antibodies to the virus in a physiological sample. Depending upon the nature of the test protocol, the peptides may be labeled or unlabeled, bound to a solid surface, conjugated to a carrier or other compounds, or the like.
The peptides of interest will be derived from the peptides encoded by the gag region or the env region. These peptides will be primarily derived from p55 or fragments thereof, e.g., p25 and p18, or gp150 and fragments thereof, e.g., gp41. These peptides will be given Roman numerals, but will also be given numerical designations which are arbitrarily associated with the manner in which they were produced.
For the gag region, of particular interest are the coding regions extending from about base pair (bp) 450 to bp 731, particularly from about bp 450 to bp 545 (97) and bp 696 to bp 731 (71); from about bp 900 to bp 1421, particularly from about bp 921 to bp 1016, including bp 921 to bp 1010; bp 972 to bp 1016 (92); and bp 936 to bp 995 (17); or from about bp 1158 to about bp 1400, particularly bp 1164 to bp 1250 (90); bp 1278 to bp 1385 (88); and bp 1320 to bp 1385 (15), of the LAV/HTLV-III retrovirus. (Numbering according to Wain-Hobson-et al., supra.)
For the env region, the regions of particular interest will be those polypeptides encoded within the bp 7210 to bp 7815 regions, particularly within bp 7231 to bp 7794, more particularly within about bp 7246 through bp 7317 (36), bp 7516 through bp 7593 (39), particularly bp 7543 through bp 7593 (79) and bp 7561 through 7593 (78), bp 7708 through bp 7779 (23), bp 7630 through bp 7689 (40), bp 7498 through bp 7554 (56).
The peptides of interest will include at least five, sometimes six, sometimes eight, sometimes 12, usually fewer than about 50, more usually fewer than about 35, and preferably fewer than about 25 amino acids included within a sequence coded for by the LAV/HTLV-III retrovirus. in each instance, desirably the oligopeptide will be as small as possible, while still maintaining substantially all of the sensitivity of the larger peptide. In some instances it may be desirable to join two or more oligopeptides which are non-overlapping in the same peptide structure or as individual peptides, which separately or together provide equivalent sensitivity to the parent.
The peptides may be modified by introducing conservative or non-conservative substitutions in the peptides, usually fewer than 20 number percent, more usually fewer than 10 number percent of the peptides being exchanged. In those situations where regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the differing epitopes of the different retroviral strains. In many instances to provide chemical and physical stability, methionine may be replaced by norleucine (Nor).
It should be understood that the polypeptides employed in the subject invention need not be identical to any particular LAV/HTLV-III polypeptide sequence, so long as the subject compounds are able to provide for immunological competition with proteins of at least one of the strains of the LAV/HTLV-III retrovirus. Therefore, the subject polypeptides may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use. By conservative substitutions is intended combinations such as gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr. Usually, the sequence will not differ by more than twenty percent from the sequence of at least one strain of an LAV/HTLV-III retrovirus except where additional amino acids may be added at either terminus for the purpose of providing an “arm” by which the peptides of this invention may be conveniently immobilized. The arms will usually be at least 1 amino acid and may be 50 or more amino acids, more often 1 to 10 amino acids.
In addition, one or two amino acids may be added to the termini of an oligopeptide or peptide to provide for ease of linking of peptides one to another, for coupling to a support or larger peptide, for reasons to be discussed subsequently, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like.
Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, may be introduced at the C- or N-terminus of the peptide or oligopeptide to provide for a useful functionality for linking. Of particular interest is the presence of from 1 to 3 cysteines at the C- or N-terminus for linking to a support. The cysteine could be linked through a disulfide linkage to a dithio- or thio-functionalized support on a thioether linkage to an activated olefin support.
In addition, the peptide or oligopeptide sequences may differ from the natural sequence by the sequence being modified by terminal-NH2 acylation, e.g., acetylation, or thioglycolic acid amidation, terminal-carboxy amidation, e.g., ammonia, methylamine, etc. In some instances, these modifications may provide sites for linking to a support or other molecule.
The peptides and oligopeptides of interest will now be considered. The first peptides of interest will be derived from the gag region, particularly the protein referred to as p25 and p18.
The peptides for p25 are as follows:
The peptide I (15) encoded in the region bp 1320 to bp 1385 will have the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Y-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Met-Met-Thr-Ala-Cys-X, where X is OH or NH2, (I) (15)
wherein the amino terminal Y, e.g., Tyr or Cys, if present, is added to facilitate coupling of the peptide to a protein carrier.
The next peptide II (17) will be encoded by the region extending from about bp 936 to bp 995 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Y-Leu-Lys-Glu-Thr-Ile-Asn-Glu-Glu-Ala-Ala-Glu-Trp-Asp-Arg-Val-His-Pro-Val-His-Ala-X, where X is OH or NH2, (II) (17)
wherein the amino terminal Y has been defined previously.
Of particular interest is the oligopeptide IIa:
Y-Ala-Ala-Glu-Trp-Asp-Arg-Z-X, (IIa)
wherein X and Y have been defined previously and Z is a bond, an amino acid which provides a means of linking, e.g., cysteine, tyrosine, etc., or taken together with X provides a functional group which may be used for linking, e.g., an olefin as in allyl or maleimidyl, dithio, etc.
The next peptide of interest, III (92), will be encoded by the region extending from about bp 972 to bp 1016 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Y-Asp-Arg-Val-His-Pro-Val-His-Ala-Gly-Pro-Ile-Ala-Pro-Gly-Gln-X, (III) (92)
wherein X, Y and Z have been defined previously.
Preferably, this peptide will have no more than about 15 amino acids encoded by the LAV/HTLV III genome.
The next peptide, IV (90), will be encoded by the region extending from about bp 1164 to bp 1250 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Y-Tyr-Ser-Pro-Thr-Ser-Ile-Leu-Asp-Ile-Arg-Gln-Gly-Pro-Lys-Glu-Pro-Arg-Asp-Tyr-Val-Asp-Arg-Phe-Tyr-Lys-Thr-Leu-Arg-Z-X, (IV) (90)
wherein X, Y and Z have been defined previously.
Preferably, this peptide will have no more than about 29 amino acids encoded by the LAV/HTLV III genome.
The peptide, V (88), will be encoded by the region extending from about bp 1278 to bp 1385 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Y-Asn-Trp-Nor-Thr-Glu-Thr-Leu-Leu-Val-Gln-Asn-Ala-Asn-Pro-Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu-Glu-Nor-Nor-Thr-A la-Cys-X, (V) (88)
wherein X and Y have been defined previously.
The next peptides of interest will be derived from the gag protein region referred to as p18.
The next peptide of interest, VI (97), will be encoded by the region extending from about bp 450 through bp 545 and will have the following sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Y-Arg-Glu-Leu-Glu-Arg-Phe-Ala-Val-Asn-Pro-Gly-Leu-Leu-Glu-Thr-Ser-Glu-Gly-Cys-Arg-Gln-Ile-Leu-Gly-Gln-Leu-Gln-Pro-Ser-Leu-Gln-Thr-X, (VI) (97)
wherein X and Y have been defined previously.
The next peptide of interest VII (71) will be encoded by the region extending from about bp 696 to bp 731. This peptide will include any oligopeptides coding for linear epitopes with the following amino acid sequence:
Y-Asp-Thr-Gly-His-Ser-Ser-Gln-Val-Ser-Gln-Asn-Tyr, (VII) (71)
wherein Y has been defined previously.
The next polypeptides of interest will be those derived from the env region, from gp110 (110 kDal).
The next peptide of interest, VIII, will be encoded by the region extending from about bp 7246 through bp 7317 and while coming within the general limitations indicated previously, will preferably have no more than 24 amino acids encoded by the LAV/HTLV III genome.
The peptide of interest will generally have the following amino acid sequence, where oligopeptides included within the following sequence will include, linear epitopes within such sequence:
Val-Lys-Ile-Glu-Pro-Leu-Gly-Val-Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Z-X, where X is OH or NH2, (VIII) (36)
wherein the carboxy terminal Z, e.g., Cys, if present, is an amino acid added to facilitate coupling of the peptide to a protein carrier.
Of particular interest is where 6, conveniently up to 4, of the naturally occurring C-terminal amino acids are deleted or substituted.
Oligopeptides contained within the above sequence of particular interest include:
Y-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Z-X (VIIIb) (50)
Y-Pro-Thr-lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-X. (VIIIb) (50)
The next peptides of interest will be derived from the env region known as gp41.
The next peptide, IX (56), will be encoded by the region extending from about bp 7498 to bp 7554, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Z-X, (IX) (56)
wherein X, Y and Z have been defined previously.
Oligopeptides contained within the above sequence of particular interest include:
Y-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Z-X (IXa) (56/39)
and
Y-Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-Z-X. (IXb) (39/56)
The next peptide of interest, X (39), will be encoded by the region from about bp 7516 through bp 7593 and has the following amino acid sequence, where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X, where X is OH or NH2. (X) (39)
The next peptide, XI (40), will be encoded by the region extending from about bp 7630 to 7689 where oligopeptides included within the following sequence will include linear epitopes within such sequence:
Y-Lys-Ser-Leu-Glu-Gln-Ile-Trp-Asn-Asn-Met-Thr-Trp-Met-Glu-Trp-Asp-Arg-Glu-Ile-Asn-Z-X, (XI) (40)
wherein Y, X and Z have been defined previously.
The next peptide of interest, XII (23), will be encoded by the region extending from about bp 7708 through bp 7779. This peptide will include any oligopeptides coding for linear epitopes within the following amino acid sequence:
Y-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Z-X, (XII) (23)
wherein X, Y and Z have been defined previously.
The next peptide of interest, XIII (79), will be encoded by the region extending from about bp 7543 through bp 7593. This peptide will include any oligopeptides coding for linear epitopes within the following amino acid sequence:
Y-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-X, (XIII) (79)
wherein X and Y have been previously defined.
The next peptide of interest, XIIIa (78), will be encoded by the region extending from about bp 7561 through bp 7593. This peptide will include any oligopeptide coding for linear epitopes within the following amino acid sequence:
Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys. (XIIIa) (78)
Of particular interest is the use of the mercaptan group of cysteines or thioglycolic acids used for acylating terminal amino groups or the like for linking two of the peptides or oligopeptides or combinations thereof by a disulfide linkage or a longer linkage. To achieve this, compounds may be employed having bis-haloacetyl groups, nitroarylhalides, or the like, where the reagents are specific for thio groups. Thus, the linking between the two mercapto groups of the different peptides or oligopeptides may be a single bond or a linking group of at least two, usually at least four, and not more than about 16, usually not more than about 14 carbon atoms. Of particular interest, is where a member of a sequence from the gag region is linked to a member from the env region. These chimeric peptides which may include non-amino acid linkages, may be further modified as will be described for the peptides and oligopeptides.
The subject peptides may be employed linked to a soluble macromolecular (e.g., ≧5 kDal) carrier. conveniently, the carrier may be a poly(amino acid), either naturally occurring or synthetic, to which antibodies are unlikely to be encountered in human serum. Illustrative polypeptides include poly-L-lysine, bovine serum albumin, keyhole limpet hemocyanin, bovine gamma globulin, etc. The choice is primarily one of convenience and availability.
With such conjugates, there will be at least one molecule of at least one subject peptide per macromolecule and not more than about 1 per 0.5 kDal, usually not more than about 1 per 2 kDal of the macromolecule. One or more different peptides may be linked to the same macromolecule.
The manner of linking is conventional, employing such reagents as p-maleimidobenzoic acid, p-methyldithiobenzoic acid, maleic acid anhydride, succinic acid anhydride, glutaraldehyde, etc. The linkage may occur at the N-terminus, C-terminus or at a site intermediate the ends of the molecule. The subject peptide may be derivatized for linking, may be linked while bound to a support, or the like.
The compounds may be employed as labeled or unlabeled compounds depending upon their use. (By label is intended a molecule which provides, directly or indirectly, a detectable signal.) Various labels may be employed, such as radionuclides, enzymes, fluorescers, chemiluminescers, enzyme substrates, cofactors or inhibitors, particles, e.g., magnetic particles, combinations of ligands and receptors, e.g., biotin and avidin, or the like. In addition, the peptides may be modified in a variety of ways for binding to a surface, e.g., microtiter plate, glass beads, chromatographic surface, e.g., paper, cellulose, silica gel, or the like. The particular manner in which the polypeptides are joined to another compound or surface is conventional and finds ample illustration in the literature. See, for example, U.S. Pat. Nos. 4,371,515; 4,487,715; and patents cited therein.
Various assay protocols may be employed for detecting the presence of either antibodies to retroviral proteins or retroviral proteins themselves. Of particular interest is using the peptide as the labeled reagent, where the label allows for a detectable signal, or binding the peptide, either directly or indirectly to a surface, where antibody to the peptide in the sample will become bound to the peptide on the surface. The presence of human antibody bound to the peptide can then be detected by employing a xenogeneic antibody specific for human immuno-globulin, normally both human IgM and IgG, or a labeled protein specific for immune complexes, e.g., Rf factor or S. aureus protein A.
Various heterogeneous protocols may be employed, either competitive or non-competitive. Peptide may be bound to a surface or support (“support”) and labeled antibody allowed to compete with antibody in the sample for the limited amount of bound peptide. The amount of label bound to the support would be related to the amount of competitive antibody in the sample.
Antibody could be bound to the support and the sample combined with labeled peptide. After contact of the reaction mixture with the bound antibody, the amount of label bound to the support would relate to the amount of cognate antibody in the sample.
Xenogeneic anti-human antibody, e.g., antibodies to the FC of IgG and IgM (immunoglobulins), could be bound to a support. The sample would be contacted with the immunoglobulins and labeled peptide, whereby the amount of labeled peptide bound to the support would be indicative of the presence of the cognate antibodies.
Alternatively, homogeneous assays can be employed where the peptide is bound to an enzyme, fluorescer, or other label, where the binding of antibody to the peptide results in being able to discriminate between the label involved with a specific binding pair complex and label which is not involved in the complex. For assays involving such techniques, see for example U.S. Pat. Nos. 3,817,837; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876, whose disclosures are incorporated herein by reference.
As an illustration of the subject invention the subject peptides may be conjugated to a fluorescent molecule, such as fluorescein, rhodamine or umbelliferone. Various techniques may be used for detecting complex formation with antibodies, e.g., fluorescence polarization. In this assay the fluorescence polarization is different between complexed and uncomplexed peptide conjugate. Apparatuses are available for measuring changes in fluorescence polarization, e.g., TDx supplied by Abbott Laboratories, Chicago, Ill.
Illustrative of an assay technique is the use of sample containers, e.g., microtiter plate wells, where the subject polypeptides or conjugates thereof are adhered to the container bottom and/or walls either covalently or non-covalently. The sample, normally human blood or serum diluted in an appropriately buffered medium, is added to the container and a sufficient time allowed for complex formation between the polypeptide(s) and any cognate antibodies in the sample. The supernatant is removed and the container washed to remove non-specifically bound proteins.
A labeled specific binding protein which specifically binds to the complex is employed for detection. To the container may be added xenogeneic antisera to human immunoglobulin, particularly anti-(human IgM and IgG) in an appropriately buffered medium. The xenogeneic antisera will normally be labeled with a detectable label, e.g., radionuclide or enzyme. Instead of antisera, proteins specific for the immune complex may be employed, e.g., S. aureus protein A. The label may then be detected. For example, with an enzyme, after removal of non-specifically bound enzyme label, a developer solution is added. The developer solution will contain an enzyme substrate and possibly enzyme cofactors, chromogens, etc., which, upon reaction, provide a colored or fluorescent product which may be detected calorimetrically or fluorimetrically, respectively.
The peptides can be prepared in a wide variety of ways. The peptides, because of their relatively short size, may be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available today and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Co., 1984; and Tam et al., J. Am. Chem. Soc. (1983) 105:6442.
Alternatively, hybrid DNA technology may be employed where a synthetic gene may be prepared by employing single strands which code for the polypeptide or substantially complementary strands thereof, where the single strands overlap and can be brought together in an annealing medium so as to hybridize. The hybridized strands may then be ligated to form the complete gene and by choice of appropriate termini, the gene may be inserted into expression vectors, which are readily available today. See, for example, Maniatis et al., Molecular Cloning, A Laboratory Manual, CSH, Cold Spring Harbor Laboratory, 1982. Or, the region of the viral genome coding for the peptide may be cloned by conventional recombinant DNA techniques and expressed (see Maniatis, supra).
DNA coding sequences which may be used for expressing peptides I-XIII are:
I (15) (TAT)GATTGTAAGACTATTTTAAAAGCATTGGGACCAG
CAGCTACACTAGAAGAAATGATGACAGCATGT
II (17) (TGT)TTAAAAGAGACCATCAATGAGGAAGCTGCAGAAT
GGGATAGAGTGCATCCAGTGCATGCA
III (92) GATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCA
GGCCAG
IV (90) TATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCA
AAAGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAA
ACTCTAAGA
V (88) AATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAAC
CCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCA
GCTACACTAGAAGAAATGATGACAGCATGT
VI (97) AGGGAGCTAGAACGATTCGCTGTTAATCCTGGCCTGTTA
GAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTA
CAACCATCCCTTCAGACA
VII (71) GACACAGGACACAGCAGCCAGGTCAGCCAAAATTAC
VIII (36) GTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCA
AAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCA(TGT)
IX (56) ATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGA
TACCTAAAGGATCAACAG(TGT)
X (39) AGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAG
CTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGC
XI (40) (TGT)AAATCTCTGGAACAGATTTGGAATAACATGACCT
GGATGGAGTGGGACAGAGAAATTAAC(TGT)
XII (23) (TGT)CATTCCTTAATTGAAGAATCGCAAAACCAGCAAG
AAAAGAATGAACAAGAATTATTGGAATTAGATAAATGG
(GGA)
XIII (79) AAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA
AAACTCATTGC
Fragments from these sequences may be employed for expression of peptide fragments, conservative base changes can be made, where the modified codon(s) code for the same amino acid(s), or non-conservative changes in the coding sequence may be made, where the resulting amino acid may be a conservative or non-conservative change.
The coding sequence may be extended at either the 5′- or 3′-terminus or both termini to extend the peptide, while retaining its epitopic site. The extension may provide for an arm for linking, e.g., to a label, such as an enzyme, for joining two or all of the peptides together in the same chain, for providing antigenic activity, or the like.
For expression, the coding sequence will be provided with start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in a cellular host, e.g., prokaryotic or eukaryotic, bacterial, yeast, mammal, etc.
The sequences by themselves, fragments thereof, or larger sequences, usually at least 15 bases, preferably at least 18 bases, may be used as probes for detection of retroviral RNA or proviral DNA. Numerous techniques are described, such as the Grunstein-Hogness technique, Southern technique, Northern technique, dot-blot, improvements thereon, as well as other methodology. See, for example, WO 83/02277 and Berent et al., Biotechniques (1985) 3:208.
Conveniently, the polypeptides may be prepared as fused proteins, where the polypeptide may be the N- or C-terminus of the fused polypeptide. The resulting fused protein could be used directly by itself as the reagent or the subject polypeptide may be cleaved from all or a portion of the remaining sequence of the fused protein. With a polypeptide where there are no internal methionines, by introducing a methionine at the fusion site, the polypeptide may be cleaved employing cyanogen bromide. Where there is an internal methionine, it would be necessary to provide for a proteolytic cleavage site, e.g., poly-lysine and/or -arginine or combinations thereof, or the internal methionine could be substituted with an amino acid such as leucine and an N-terminal methionine added for cyanogen bromide cleavage. A wide variety of proteases, including dipeptidases, are well known and the appropriate processing signal could be introduced at the proper site. The processing signal may have tandem repeats so as to insure cleavage, since the presence of one or more extraneous amino acids will not interfere with the utility of the subject polypeptides.
Depending upon the nature of the assay, the physiological sample, e.g., saliva, blood, plasma, or serum, may be pretreated by dilution into an assay medium, which will usually be an aqueous buffered medium employing one of a variety of buffers, such as phosphate, tris, or the like. A preferred diluent is blotto (5% w/v nonfat dry milk, 0.01% thimerosal, 0.01% Antifoam A in 0.01 M sodium phosphate, pH 7.2, and 0.15 M NaCl). Usually the pH will be in the range of about 6 to 9. The sample will then be combined with the reagent in accordance with the appropriate protocol and sufficient time allowed for binding. Where a heterogeneous system is used, usually the stages will be followed by washes, to minimize non-specific binding. At the end of the procedure, the label will be detected in accordance with conventional ways.
Besides the use of the subject peptides and their analogs in assays, the subject peptides may also find use by themselves or in combination in vaccines. The peptides may be formulated in a convenient manner, generally at concentrations in the range of 1 μg to 20 mg/kg of host. Physiologically acceptable media may be used as carriers, such as sterile water, saline, phosphate buffered saline, and the like. Adjuvants may be employed, such as aluminum hydroxide gel, or the like. Administration may be by injection, e.g., intramuscularly, peritoneally, subcutaneously, intravenously, etc. Administration may be one or a plurality of times, usually at one to four week intervals.
The following examples are offered by way of illustration and not by way of limitation.
EXPERIMENTAL
Peptides 15, 71, 88, 90, 92 and 97 were assembled on a t-butyloxycarbonyl (BOC)-methylbenzyl-cysteine-phenyl-acetamidomethyl (PAM) polystyrene/divinylbenzene resin (Applied Biosystems, Inc., Foster City, Calif.). For carboxamide peptides 78 and 79 p-methylbenzhydrylamine polystyrene/divinylbenzene was used. Symmetrical anhydride couplings were carried out in an Applied Biosystems 430A synthesizer, except that glutamine and asparagine were coupled as hydroxybenzo-triazole esters. Benzyl based side chain protection and BOC alpha-amine protection were used. Tryptophan was protected by the formyl moiety, methionine was protected by its sulfoxide, and dinitrophenol was used for protecting histidine. Protecting groups were removed by conventional procedures.
Peptide 36 was assembled on a benzhydrylamine polystyrene/divinylbenzene resin in a Beckman 990 peptide synthesizer (Beckman Instruments, La Brea, Calif.). Benzyl based side chain protection and BOC alpha-amine protection were used. All the residues were added by the direct dicyclohexylcarbodiimide method, except for glutamine which was coupled as the hydroxybenzotriazole ester.
Peptide 39 was synthesized on a benzhydryl-amine resin as described for peptide 36 with asparagine also being coupled as the ester.
When the peptides were radiolabeled, it was by acetylating the amino terminus with 3H-acetic acid and an excess of dicyclohexylcarbodiimide.
The peptides were deprotected and cleaved from the resin by the Tam “low-high” HF protocol (Tam et al., supra). Peptides 36, 39, 79, 78, 88, 90, 92 and 97 were extracted from the resin in 5% acetic acid and subjected to gel filtration chromatography in 5% acetic acid. Peptides 15 and 71 were extracted in 0.5M ammonium carbonate/0.001M dithiothreitol (DTT) and chromatographed in 0.05M ammonium carbonate/0.005M β-mercaptoethanol. Fractions containing the peptide were pooled and lyophilized. The integrity of the synthetic products was assured by ninhydrin monitoring after each coupling and by analytical reverse phase chromatography and amino acid analysis.
Peptides 90, 92 and 97 were polymerized by oxidation of their sulfhydryls to intermolecular disulfides. Briefly, the lyophilized reduced peptide was dissolved in minimal 6M guanidine HCl/0.1M sodium phosphate, pH 9.0, and allowed to oxidize overnight at room temperature.
Peptides 15, 23, 36, 40, 49, 50 and 56 synthesized above were conjugated to bovine serum albumin (BSA) which had been derivatized with N-succinimidyl-4 -(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), essentially as described by Ishikawa et al., J. of Immunoassay (1983) 4:209.
To 2 ml of a BSA solution (20 mg/ml in 0.1M potassium phosphate, pH 7.0) at 30° C. was added 1.5 ml of an SMCC solution (8 mg/ml in dimethylformamide). The mixture was stirred magnetically for 1 hr, after which it was centrifuged to remove any precipitated albumin. The clarified mixture was then subjected to gel filtration on Sephadex G-25 equilibrated in 0.1M potassium phosphate, pH 6.0. The protein-containing fractions, as determined by their absorbance at 280 nm, were pooled and stored frozen at −70° C. until needed.
The peptides synthesized above were dissolved in 0.1M sodium phosphate, pH 8.0 to a concentration of 5 mg/ml (peptide 36), 8 mg/ml (peptide 15) or 1.6 mg/ml (peptide 39). To 1.5 ml of each solution was added 2 mg of solid DTT. The solutions were stirred for 30 min at 30° C., after which they were subjected to gel filtration chromatography on Sephadex G-10, equilibrated in 0.1M potassium phosphate, pH 6.0. The tritium-containing fractions, as determined by scintillography of aliquots, were pooled and mixed with 1 ml (0.5 ml for peptide V) of SMCC-derivatized BSA. The resultant mixtures were stirred at 30° C. for 12 hr and then dialyzed exhaustively against water.
The other peptides were prepared in accordance with the procedures described above and conjugated to BSA in accordance with the above described procedures. The ratio of peptide to BSA was determined by employing radiotracers in accordance with conventional ways.
mols peptide
mol BSA
I (15) 14
II (17)  5
VIII (36)  9
IX (56) 17
X (39)  6
XI (40) 18
XII (23)  30*
*may be erroneous and could be as high as 55.
Analysis by ELISA
The lyophilized peptide or protein/peptide conjugate was dissolved in 6M guanidine HCl. The guanidine solutions were diluted in 0.05M carbonate/bicarbonate buffer (pH 9.6) to a final peptide concentration of 8 to 40 μg/ml just prior to plating in the 96-well plates. Fifty μl of peptide solution were aliquoted per microtiter well and incubated at 4° C. overnight. Plates were then blocked with BLOTTO (5% [w/v] nonfat dry milk/0.01% thimerosal/0.01% antifoam A in 0.01M sodium phosphate, pH 7.2/0.15M sodium chloride) for one hour at 37° C. Sera were diluted 1:100 with a 1:1 mixture of BLOTTO and PBS (0.01M sodium phosphate, pH 7.3/0.15M NaCl), and 50 μl of diluted sera was added to each well and incubated for one hour at 37° C. The sera were removed and the plates were washed three times in wash buffer (0.15M NaCl/0.05% [w/v] Tween 20) before adding 100 μl of the goat anti-human IgG/horseradish peroxidase conjugate (50% stock diluted 1:10,000 in 50 mM sodium citrate/0.05% Tween 20/1% heat-inactivated normal goat serum; obtained from Antibodies, Inc., Davis, Calif.) for one hour at 37° C. The conjugate was removed and the plates washed three times with 0.15M NaCl/0.05% (w/v) Tween 20. The ELISA was developed by adding 100 μl per well of substrate solution (10 mg 3,3′,5,5′-tetramethylbenzidine in 50 ml 0.05M sodium citrate, pH 7.0) for 30 min at room temperature. Reactions were stopped with 100 μl per well of 3N H2SO4, and the optical density at 450 nm determined by an automated ELISA reader.
Summary of Table 1
Table 1 gives ELISA results for all petpides that are immunoreactive.
Peptides 49 and 50 are part of peptide 36.
Peptide 56 partially overlaps peptide 39.
Peptide 49-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 50-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 56-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 40-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 23-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 15-BSA reactive with 10/10 positive sera; not reactive with 2/2 negative sera.
Peptide 36-BSA reactive with 9/10 positive sera; not reactive with 2/2 negative sera.
In a larger panel, peptide 56 which partially overlaps peptide 39, is not reactive with all sera that are reactive with peptide 39. This suggests that there are at least two reactive epitopes within peptide 39 or that peptides 39 and 56 contain non overlapping reactive epitopes.
Peptide 23 (both conjugated to BSA and unconjugated) was further tested against a larger panel of sera (23 positives, 8 negatives) and displays a sensitivity of 80-90%.
Summary of Table 2
Table 2 shows that two of the peptides derived from the gag region (#15 and #17) are reactive with LAV seropositive sera that are poorly reactive or unreactive with peptide 39. This supports the use of a combination of gag and env peptides to produce a more sensitive assay.
Summary of Table 3
Table 3 compares results obtained with peptides 15-BSA and 39 with results obtained with these peptides physically mixed (15-BSA+39) or chemically combined (thiol-oxidized 15+39).
The result obtained when positive samples are assayed with either the physical or chemical combination of peptides 15 and 39 is generally higher than that obtained with either peptide alone. This is clearly demonstrated with samples 126, 131, 135, 138 and 1296.
Summary of Table 4
Table 4 compares results obtained with peptides 71, 78, 79, 88, 90, 92 and 97 in an ELISA assay. All of the peptides except one provide better than 70% correlation for positives and two peptides had 100% correlation.
TABLE 1
COMPARISON OF PEPTIDES WITH A WHOLE VIRUS LYSATE IN
AN ELISA ASSAY FOR THE DETECTION OF ANTIBODIES TO LAV
ELISA Using
Positive Whole Virus Confirmed as BSA- BSA- BSA- BSA- BSA- BSA- BSA-
Sera Diagnosis Lysate1 Serpositive2 Pep15 Pep36 Pep49 Pep50 Pep39 Pep56 Pep40 Pep23 Pep 23
155 LAS and/or 1.069 yes 0.525 1.679 0.955 1.678 1.167 1.675 0.603 1.640 0.111
homosexual
124 LAS and/or 1.189 yes 1.329 1.465 1.334 2.207 1.073 1.842 1.462 2.117 2.127
homosexual
138 LAS and/or 1.302 yes 0.378 0.159 0.204 0.374 0.514 0.643 0.774 0.960 0.106
homosexual
133 LAS and/or 1.250 yes 0.365 0.567 0.409 0.581 1.036 0.627 1.297 2.077 N.D.
homosexual
131 LAS and/or 1.220 yes 0.411 0.272 0.225 0.595 0.448 1.679 1.209 1.621 0.949
homosexual
134 LAS and/or 1.050 yes 0.559 0.712 0.729 0.293 1.619 2.170 0.567 1.705 1.552
homosexual
153 LAS and/or 2.000 yes 0.467 0.548 1.011 0.591 1.314 1.324 0.734 0.970 0.524
homosexual
157 LAS and/or 1.349 yes 0.366 0.321 0.148 0.427 1.326 2.179 1.153 2.017 1.158
homosexual
Y-1/ LAS and/or 2.000 yes 2.109 1.022 1.547 1.928 1.305 2.115 1.257 1.565 0.762
CDC homosexual
501 LAS and/or 1.109 yes 2.374 1.168 1.938 2.209 1.167 1.170 0.625 0.467 0.059
homosexual
1892  Healthy n.d. n.d.* 0.128 0.113 0.119 0.124 0.045 0.143 0.141 0.253 0.034
heterosexual
639 Healthy 0.123 not 0.159 0.142 0.102 0.186 0.038 0.355 0.251 0.286 0.024
heterosexual seropositive
TABLE 2
COMPARISON OF GAG PEPTIDES WITH PEPTIDE 39 IN AN
ELISA ASSAY FOR THE DETECTION OF ANTIBODIES TO LAV
Whole Confirmed
Serum Virus as
No. Diagnosis Lysate1 Seropositive2 17-BSA 15-BSA 39
1296 Blood Donor 2.01 yes 0.633 0.65 0.11
501 Unknown 1.109 yes 0.18 2.04 2.15
129 LAS and/or 1.08 yes 0.62 0.49 0.42
homosexual
154 LAS and/or 1.41 yes 0.26 0.26 0.35
homosexual
7 LAS and/or 2.00 yes 0.79 1.02 0.22
homosexual
641 Healthy 0.20 n.d. 0.22 0.19 0.04
heterosexual
639 Healthy 0.12 n.d. 0.20 0.16 0.05
heterosexual
TABLE 3
COMPARISON OF PEPTIDES 15 and 39 INDIVIDUALLY WITH PEPTIDES 15 AND 39
PHYSICALLY OR CHEMICALLY COMBINED IN AN ELISA ASSAY FOR THE
DETECTION OF ANTIBODIES TO LAV
Serum Whole Virus Confirmed as 15-BSA Thiol-oxidized
No. Diagnosis Lysate1 Seropositive2 15-BSA 39 39 15 + 39
133 LAS and/or 1.250 yes 0.13 1.02 >2 1.88
homosexual
134 LAS and/or 1.050 yes 0.21 1.62 >2 2.27
homosexual
135 LAS and/or 1.310 yes 0.25 0.32 1.93 1.48
homosexual
138 LAS and/or 1.302 yes 0.13 0.51 1.65 0.91
homosexual
153 LAS and/or 2.000 yes 0.16 1.32 n.d. 1.89
homosexual
154 LAS and/or 1.41 yes 0.19 0.35 n.d. 1.35
homosexual
155 LAS and/or 1.069 yes 0.29 1.17 n.d. 1.83
homosexual
157 LAS and/or 1.349 yes 0.14 1.33 n.d. n.d.
homosexual
666 Unknown 2.000 yes 1.60 1.39 >2 2.01
1296  Blood Donor 2.00 yes 0.65 0.11 0.99 0.16
633 Healthy 0.222 not sero- 0.09 0.05 n.d. n.d.
heterosexual positive
637 Healthy 0.097 not sero- 0.13 0.04 0.42 n.d.
heterosexual positive
639 Healthy 0.123 not sero- 0.12 0.04 0.22 0.11
heterosexual positive
641 Healthy 0.199 not sero- 0.18 0.03 0.49 0.13
heterosexual positive
501 Positive 1.109 yes 1.39 1.17 >2.0 1.77
control
Y-1 Positive 2.000 yes 1.02 1.30 >2.0 2.02
CDC control pool
120 LAS3 and/or 1.540 yes 0.19 1.37 n.d. n.d.
homosexual
121 LAS and/or 1.483 yes 0.09 1.51 >2.0 1.96
homosexual
122 LAS and/or 1.283 yes 0.14 1.88 >2.0 2.33
homosexual
124 LAS and/or 1.189 yes 0.60 1.06 n.d. n.d.
homosexual
125 LAS and/or 1.232 yes 0.18 1.53 n.d. n.d.
homosexual
126 LAS and/or 1.233 yes 0.24 0.51 >2 1.5
homosexual
127 LAS and/or 1.046 yes 0.25 1.52 n.d. n.d.
homosexual
128 LAS and/or 1.284 yes 0.09 1.07 n.d. n.d.
homosexual
129 LAS and/or 1.081 yes 0.33 0.42 n.d. n.d.
homosexual
130 LAS and/or 0.912 yes 0.28 1.17 n.d. n.d.
homosexual
131 LAS and/or 1.220 yes 0.14 0.45 >2 1.22
homosexual
132 LAS and/or 1.237 yes 0.15 1.24 >2 1.91
homosexual
667 Healthy 0.095 n.d. 0.15 0.04 0.42 n.d.
hetersexual
1890  Healthy n.d. n.d. 0.15 0.05 0.39 0.15
heterosexual
1891  Healthy n.d. n.d. 0.17 0.05 0.31 0.12
heterosexual
1892  Healthy n.d. n.d. 0.08 0.05 0.18 0.07
heterosexual
TABLE 4
COMPARISON OF PEPTIDES 92, 90, 88, 97, 71, 79 and 78 IN AN
ELISA ASSAY FOR THE DETECTION OF ANTIBODIES TO LAV
Confirmed
Serum as Sero-
No. positive 92 90 88 97 71 79 78
127 yes .201 1.256 1.610 2.558 .476 2.346 .520
130 yes .220 .900 1.912 2.341 .350 1.808 .438
124 yes .105 1.175 .372 2.302 .514 1.086 .092
125 yes .126 1.386 1.798 .395 .416 2.266 .281
128 yes .122 .882 .201 .377 .246 1.144 .123
134 yes .131 1.159 .358 2.455 .535 1.316 .118
135 yes .120 .644 .157 1.231 .292 .381 .119
153 yes .138 1.150 .180 .780 .352 1.039 .146
154 yes ND .623 .256 .365 .210 ND ND
155 yes .108 .845 .058 1.984 .185 1.584 .105
157 yes .118 .936 .942 1.620 .536 1.162 .146
120 yes .159 1.031 .740 .221 .362 1.546 .239
121 yes .157 1.284 1.776 .396 .307 2.084 .205
132 yes .100 .909 .422 .399 .398 1.386 .192
138 yes .086 .495 ND 1.201 .285 .312 .093
133 yes .100 .739 .143 .526 .312 .597 .114
131 yes .112 .841 .197 .742 .188 1.150 .101
501 yes .472 1.098 2.058 2.253 .341 1.768 .216
129 yes .091 ND ND ND ND .562 .085
Y1 yes ND ND 2.228 ND ND ND ND
N3 no .074 .603 .106 .162 .101 .224 .076
N12 no .075 .617 .131 .174 .088 .174 .056
N4 no .058 .519 .128 .190 .090 .172 .040
639 no .082 .474 .092 .115 .121 .153 .059
641 no .081 .369 .090 .155 .169 .140 .085
N13 no .079 .455 .111 .120 .100 .226 .122
N14 no .054 .560 .098 .151 .085 .162 .070
N16 no .077 .521 .083 .122 .070 .183 .079
Cutoff 0.10 0.70 0.20 0.20 0.20 0.30 0.20
Fraction of Confirmed 14/18 15/18 13/18 18/18 16/18 18/18 6/18
Seropositive Samples
Detected as Positive
FOOTNOTES TO TABLES 1-3
1 Prepared as described in U.K. application Serial No. 83/24800, filed Sep. 15, 1983.
2 Radiolabeled LAV antigens were disrupted in RIPA buffer (Gilead et al., Nature (1976) 264:263) and then were reacted with human serum. The resultant immune complexes were separated by binding to a Staphylococcus aureus adsorbent (Kessler, J. Immunology (1975) 115:1617) followed by multiple washings. Immuneprecipitated antigens were analyzed by SDS polyacrylamide gel electrophoresis (Laemmli, Nature (1970) 227:680) followed by fluorography. Presence of either a p25 or gp43 band was considered necessary and sufficient to confirm a sample as seropositive.
3 LAS=lymphadenopathy syndrome.
4 N.D.=not determined.
It is evident from the foregoing results that by employing one or a combination of peptides of the subject invention, a sensitive accurate test for the presence of antibodies to AIDS is provided. The subject peptides can be used by themselves or in combination with a screening assay or confirmatory assay, where the complete lysate or complete antigens may be employed as an independent procedure. Furthermore, because of the specificities of the peptides, one would anticipate that the DNA sequences coding for the peptides would also find similar specificity in a DNA hybridization assay. Thus, the subject invention allows for the detection of patients who have been exposed to the retroviral etiologic agent of lymphadenopathy syndrome and/or AIDS.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Claims (27)

What is claimed is:
1. A method for determining the presence of antibodies to LAV/HTLV-III in a test sample suspected of containing said antibodies, said method comprising:
combining the test sample with a peptide immunoreactive with antibodies to LAV/HTLV-III having from eleven amino acids to about thirty-five amino acids, wherein the amino acid sequence of said peptide is a contiguous LAV/HTLV-III sequence and includes at least eleven amino acids from the following sequence:
Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys and peptide analogues thereof having a sequence of a LAV/HTLV-III strain and having immunoreactivity to antibodies to LAV/HTLV-III;
incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III; and
determining the formation of immune complex and thereby detecting the presence or absence of said antibodies.
2. The method according to claim 1, wherein the peptide is:
Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys.
3. The method according to claim 1, wherein the peptide is:
Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys.
4. The method according to claim 1, wherein the peptide is:
Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys.
5. The method according to claim 1, wherein the peptide is adsorbed to a solid support.
6. The method according to claim 5, wherein the solid support is coated with a peptide of the following sequence:
Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys.
7. The method according to claim 5, wherein the step of determining comprises introducing a labeled antibody which binds a human antibody to produce a detectable signal.
8. The method according to claim 7, wherein the label-is an enzyme.
9. The method according to claim 7, wherein the label is a radionuclide.
10. The method according to claim 1, wherein for each test sample determination the peptide is in an amount of from about 0.4 ug to about 2 ug.
11. A method for determining the presence of antibodies to LAV/HTLV-III in a subject, said method comprising:
combining a test sample from the subject with a peptide immunoreactive with antibodies to LAV/HTLV-III having from eleven amino acids to about thirty-five amino acids, wherein the amino acid sequence of said peptide is a contiguous LAV/HTLV-III sequence and includes at least eleven amino acids from the following sequence: Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys;
incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III; and
determining the formation of immune complex and therefrom determining the presence of antibodies to LAV/HTLV-III in the subject.
12. A test kit for determining the presence of antibodies to LAV/HTLV-III in a test sample, comprising a solid support to which is adsorbed a peptide immunoreactive with antibodies to LAV/HTLV-III having from eleven amino acids to about thirty-five amino acids, wherein the amino acid sequence of said peptide is a contiguous LAV/HTLV-III sequence and includes at least eleven amino acids from the following sequence:
Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys
and peptide analogues thereof having a sequence of a LAV/HTLV-III strain and immunoreactive to antibodies to LAV/HTLV-III, or conjugates of the peptides and analogues.
13. The test kit according to claim 12, further comprising a container having a positive control sample having antibodies to LAV/HTLV-III virus and a negative control sample lacking antibodies to said virus.
14. The test kit according to claim 13, further comprising a buffer solution for diluting the test sample.
15. The test kit according to claim 14, further comprising a labeled specific binding protein which binds to said antibodies and provides a detectable signal.
16. The kit according to claim 15, wherein the labeled specific binding protein is an antibody which binds a human antibody.
17. The kit according to claim 16, wherein the specific binding protein is an antibody labeled with an enzyme.
18. The kit according to claim 16, wherein the specific binding protein is an antibody labeled with a radionuclide.
19. The kit according to claim 17, further comprising an enzyme substrate which, upon reaction, provides a colored or fluorescent product.
20. The kit according to claim 19, further comprising a solution to stop the development of the colored product.
21. The kit according to claim 12, wherein the solid support is a bead or a microtiter plate.
22. The method according to claim 1, wherein the test sample is human serum or plasma.
23. The method according to claim 1, wherein the test sample is human serum or plasma.
24. The test kit according to claim 12, wherein the sample to be tested is human serum or plasma.
25. A method for determining the presence of antibodies to LAV/HTLV-III said method comprising:
combining a test sample with a peptide immunoreactive with antibodies to LAV/HTLV-III wherein the sequence of said peptide is:
RILAVERYLKNQQLLGIWGCSGKLIC;
incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III; and
determining the formation of immune complex.
26. A method for determining the presence of antibodies to LAV/HTLV-III said method comprising:
combining a test sample with a peptide immunoreactive with antibodies to LAV/HTLV-III wherein the sequence of said peptide is:
IKQLQARILAVERYLKNQQ;
incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III; and
determining the formation of immune complex.
27. A method for determining the presence of antibodies to LAV/HTLV-III said method comprising:
combining a test sample with a peptide immunoreactive with antibodies to LAV/HTLV-III wherein the sequence of said peptide is:
KNQQLLGIWGCSGKLIC;
incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III; and
determining the formation of immune complex.
US07/541,163 1985-04-29 1990-06-20 Synthetic antigen for the detection of AIDS-related disease Expired - Lifetime US6485900B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US07/541,163 US6485900B1 (en) 1985-04-29 1990-06-20 Synthetic antigen for the detection of AIDS-related disease
US08/245,516 US6130314A (en) 1986-03-26 1994-05-18 Synthetic antigen for the detection of AIDS-related disease
US08/252,987 US6214539B1 (en) 1985-04-29 1994-06-01 Synthetic antigen the detection of aids-related disease
US10/305,271 US20030211117A1 (en) 1985-04-29 2002-11-26 Synthetic antigen for the detection of aids-related disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72805285A 1985-04-29 1985-04-29
US06/767,303 US4629783A (en) 1985-04-29 1985-08-19 Synthetic antigen for the detection of AIDS-related disease
US84448586A 1986-03-26 1986-03-26
US07/541,163 US6485900B1 (en) 1985-04-29 1990-06-20 Synthetic antigen for the detection of AIDS-related disease

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US06/767,303 Continuation-In-Part US4629783A (en) 1985-04-29 1985-08-19 Synthetic antigen for the detection of AIDS-related disease
US84448586A Continuation 1985-04-29 1986-03-26

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US83951292A Continuation 1985-04-29 1992-02-20
US83951192A Division 1986-03-26 1992-02-20
US10/305,271 Continuation US20030211117A1 (en) 1985-04-29 2002-11-26 Synthetic antigen for the detection of aids-related disease

Publications (1)

Publication Number Publication Date
US6485900B1 true US6485900B1 (en) 2002-11-26

Family

ID=27419109

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/541,163 Expired - Lifetime US6485900B1 (en) 1985-04-29 1990-06-20 Synthetic antigen for the detection of AIDS-related disease
US08/252,987 Expired - Lifetime US6214539B1 (en) 1985-04-29 1994-06-01 Synthetic antigen the detection of aids-related disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/252,987 Expired - Lifetime US6214539B1 (en) 1985-04-29 1994-06-01 Synthetic antigen the detection of aids-related disease

Country Status (8)

Country Link
US (2) US6485900B1 (en)
EP (1) EP0220273B2 (en)
KR (1) KR910002374B1 (en)
AT (1) ATE116006T1 (en)
DE (1) DE3650175T3 (en)
DK (2) DK171250B1 (en)
FI (1) FI91073C (en)
WO (1) WO1986006414A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273695B1 (en) 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
JP2702911B2 (en) * 1985-09-11 1998-01-26 ユナイテツド・バイオメデイカル・インコ−ポレ−テツド Synthetic peptide, and method for detecting AIDS and pre-AIDS using the same
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
US7115363B1 (en) 1986-01-22 2006-10-03 Institut Pasteur Retrovirus capable of causing AIDS, means and methods for detecting it in vitro
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
FR2625100A2 (en) * 1986-03-13 1989-06-30 Lurhuma Zirimwabagabo Use of antigens for the preparation of vaccines, protein rendered immunogenic and pharmaceutical composition containing it
US5075211A (en) * 1986-03-26 1991-12-24 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4879212A (en) * 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US5087557A (en) * 1986-06-23 1992-02-11 Genetic Systems Corporation Human monoclonal antibody to lymphadenopathy-associated virus
DK169582B1 (en) * 1986-06-23 1994-12-12 Squibb Bristol Myers Co Human monoclonal antibody capable of reacting with an epitope on the LAV / HTLV-III envelope glycoprotein gp41, cell lines producing such antibody, pharmaceutical preparation containing the antibody, and method for determining the presence of LAV / HTLV-III in a biological sample. and method for separating specific antigenic determinants of LAV / HTLV-III using ant
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
AU1366088A (en) * 1987-01-28 1988-08-24 Ortho Pharmaceutical Corporation Immunosuppressive peptides and methods of use
ES2058259T5 (en) * 1987-03-25 2000-09-01 Genetic Systems Corp SYNTHETIC ANTIGENS FOR THE DETECTION OF AIDS-RELATED DISEASE CAUSED BY LAV-2.
NO881151L (en) * 1987-03-27 1988-09-28 Syntello Ab SYNTHETIC HIV-1 ANTIGEN.
SE8701628D0 (en) * 1987-04-16 1987-04-16 Erling Norrby MEANS OF ANALYSIS MM
CA1339363C (en) * 1987-05-01 1997-08-26 Alan Ray Flesher Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
US4921787A (en) * 1987-05-01 1990-05-01 Cambridge Bioscience Corporation Detection of antibodies to human immunodeficiency virus by agglutination of antigen coated latex
FI872409A0 (en) * 1987-05-29 1987-05-29 Labsystems Oy FOERFARANDE FOER DETEKTERING AV HIV-1 MOTKROPPAR.
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
ES2051859T3 (en) * 1987-09-04 1994-07-01 Int Murex Tech Corp SOLID PHASE IMMUNO ASSAY FOR AN ANTIBODY AND BIOLOGICAL STRUCTURES FOR USE THEREOF.
SE8704185L (en) * 1987-10-28 1989-04-29 Ferring Ab NEW PEPTIDES, ARTIFICIAL ANTIGENS AND IMMUNO ANALYSIS TEST RATES
US7442525B1 (en) 1987-12-24 2008-10-28 Novartis Vaccines And Diagnostics, Inc. Method for expressing HIV polypeptides
SE8705197D0 (en) * 1987-12-30 1987-12-30 Jonas Blomberg NEW PEPTIDES, TWO DIAGNOSTIC METHODS USING THE PEPTIDES AND A MEDICATION BASED ON THE PEPTIDES
US5241047A (en) * 1988-12-08 1993-08-31 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6218102B1 (en) * 1988-01-27 2001-04-17 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6210874B1 (en) 1988-01-27 2001-04-03 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6214537B1 (en) 1988-01-27 2001-04-10 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
DE68925660T2 (en) * 1988-06-10 1996-09-26 United Biomedical Inc HIV peptide fragments
GB8828097D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
GB8828098D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
WO1991008227A1 (en) * 1989-11-27 1991-06-13 Replico Medical Aktiebolag NEW HIV-1 p17 PEPTIDES, DIAGNOSTIC ANTIGENS AND IMMUNOASSAY METHOD
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
FR2657017B1 (en) * 1990-01-16 1995-08-18 Clonatec Sa PEPTIDES DERIVED FROM THE GLYCOPROTEIN ENVELOPE OF THE HIV-1 VIRUS, THEIR APPLICATIONS FOR THE DETECTION OF AN INFECTION DUE TO THIS VIRUS AND FOR VACCINATION AGAINST AIDS.
DE69129207T2 (en) * 1990-01-16 1998-10-08 Orgenics Ltd Peptides derived from virus-HIV-envelope glycoproteins, their use for the detection of infection of these viruses and for the vaccination against AIDS
SE468168B (en) * 1990-02-20 1992-11-16 Replico Medical Ab HIV-1, P24 PEPTIDES, DIAGNOSTIC ANTIGENS AND PROCEDURES FOR DIFFERENTIAL DIAGNOSTICS OF PRELIMINARY HIV-1 POSITIVE SERUM TESTS
SE470074B (en) * 1990-08-16 1993-11-01 Replico Medical Ab Method for diagnosis of picorene and / or flavivirus infection, peptides, diagnostic antigens and vaccine composition with these peptides
DE4039925A1 (en) * 1990-12-14 1992-06-17 Behringwerke Ag SELECTED PEPTIDES OF THE GROUP-SPECIFIC ANTIGEN (GAG) OF HUMANEM IMMUNE DEFICIENCY VIRUS (HIV), THEIR PRODUCTION AND USE
AU4387193A (en) * 1992-05-29 1993-12-30 Abbott Laboratories Ligase chain reaction starting with rna sequences
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2732346B1 (en) * 1995-03-27 1997-05-30 Centre Nat Rech Scient MUTE PROTEINS, ENCODED BY LENTIVIRUS MUTE GENES, PEPTIDE FRAGMENTS INCLUDED IN SAID PROTEINS, EXPRESSION VECTORS EXPRESSING MUTE PROTEINS AND THEIR APPLICATIONS
FR2773156B1 (en) * 1997-12-26 2000-03-31 Biovacs Inc NOVEL ANTI-RETROVIRAL IMMUNOGENS (TOXOIDS), NOVEL PREPARATION METHODS AND APPLICATION TO AIDS PREVENTION AND TREATMENT
FR2781158B1 (en) 1998-07-15 2002-12-13 Vacs Internat NOVEL MODIFIED NON-IMMUNOSUPPRESSIVE IMMUNOGENIC PROTEINS, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
CA2676762C (en) * 1998-11-30 2015-12-29 Ortho-Clinical Diagnostics, Inc. Peptides for the detection of hiv-1 group o
FR2802426B1 (en) 1999-12-15 2004-04-02 Neovacs USE OF IMMUNOSUPPRESSIVE AND / OR ANGIOGENIC IMMUNOGENIC PROTEINS MADE INACTIVE FOR THE PRODUCTION OF SECRETORY IGAs
EP1466924B9 (en) * 2003-04-11 2013-06-19 Institut Pasteur Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
FR2882557A1 (en) * 2005-02-25 2006-09-01 Centre Nat Rech Scient New peptides containing a T cell epitope from p24 antigen of human immune deficiency virus, useful for treatment and prevention of infections, also for determining a subject's immune status
KR102564360B1 (en) 2015-02-09 2023-08-04 슬링샷 바이오사이언시즈 인코포레이티드 Hydrogel particles with tunable optical properties and methods for using the same

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8429099D0 (en) 1984-11-16 1984-12-27 Pasteur Institut Closed dna sequences
GB8501473D0 (en) 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
US4520113A (en) 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
WO1986002383A1 (en) 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
FR2571968A1 (en) 1984-10-18 1986-04-25 Pasteur Institut Purified lymphadenopathy and acquired immune deficiency syndrome virus and envelope antigens of this virus, method for obtaining this virus and these envelope antigens of this virus, uses of this virus or of these antigens in the preparation of immunogenic compositions or for the diagnosis of the abovementioned pathologies
US4708818A (en) 1983-09-15 1987-11-24 Institut Pasteur Human immunodeficiency viruses associated with Acquired Immune Deficiency Syndrome (AIDS), a diagnostic method for AIDS and pre-AIDS, and a kit therefor
US4735896A (en) * 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
US4753873A (en) 1986-02-03 1988-06-28 Cambridge Bioscience Corporation Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
US4774175A (en) 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4784941A (en) 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
US4808536A (en) 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4843011A (en) 1985-08-01 1989-06-27 Akzo N.V. Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production
US4861707A (en) 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
US4879212A (en) 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US4943628A (en) 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
US4956273A (en) 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
US4957737A (en) 1986-05-27 1990-09-18 Hoffmann-La Roche Inc. HTLV-III (LAV) envelope peptides
US5017688A (en) 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4803156A (en) * 1985-09-11 1989-02-07 New York Blood Center Peptide-beta-lactamase conjugates for enzyme-linked immunoassays
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708818A (en) 1983-09-15 1987-11-24 Institut Pasteur Human immunodeficiency viruses associated with Acquired Immune Deficiency Syndrome (AIDS), a diagnostic method for AIDS and pre-AIDS, and a kit therefor
US4520113A (en) 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
WO1986002383A1 (en) 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
FR2571968A1 (en) 1984-10-18 1986-04-25 Pasteur Institut Purified lymphadenopathy and acquired immune deficiency syndrome virus and envelope antigens of this virus, method for obtaining this virus and these envelope antigens of this virus, uses of this virus or of these antigens in the preparation of immunogenic compositions or for the diagnosis of the abovementioned pathologies
GB8429099D0 (en) 1984-11-16 1984-12-27 Pasteur Institut Closed dna sequences
GB8501473D0 (en) 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
WO1986004336A1 (en) 1985-01-21 1986-07-31 Institut Pasteur Monoclonal antibodies against core proteins of lymphadenopathy-associated-viruses
US4774175A (en) 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4784941A (en) 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
US4843011A (en) 1985-08-01 1989-06-27 Akzo N.V. Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production
US4956273A (en) 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4753873A (en) 1986-02-03 1988-06-28 Cambridge Bioscience Corporation Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
US4808536A (en) 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US4735896A (en) * 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
US4879212A (en) 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US4957737A (en) 1986-05-27 1990-09-18 Hoffmann-La Roche Inc. HTLV-III (LAV) envelope peptides
US5017688A (en) 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US4861707A (en) 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
US4943628A (en) 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
Allan et al., Science 228:1091-1099 (1985).
Barin et al, "Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS Patients" Science 228 (May 31, 1985) 1094-1096.* *
Brun-Vezinet et al., Lancet I:1253-1256 (1984).
Budiansky, "False Test Results Raise Doubts" Nature 312 (Dec. 13, 1984) 583. *
Cabradilla et al, "Serodiagnosis of Antibodies to the Human AIDS Retrovirus with Bacterially Synthesized env Polypeptide" Bio/technology 4 (Feb./1986) 128-133.* *
Chang et al "An HTLV-III peptide produced by recombinant DNA is immunoreative with sera from patients with AIDS" Nature 315 (May 9, 1985) 151-154.* *
Chang et al "Expression in Escherichia coli of Open Reading Frame Gene Segments of HTLV-III" Science 228 (Apr. 5, 1985) 93-96.* *
Chang et al, "Detection of Antibodies to Human T-Cell Lyphotropic Virus-III (HTLV-III) with an Immunoassay Employing a Recombinant Escherichia coli-Derived Viral Anti-genic Peptide" Bio/technology 3 (Oct./1985) 905-909.* *
Crowl et al., Cell 41:979-986 (1985).
Hahn et al., Nature 312:166-169 (1984).
Hopp and Woods, Proc. Natl. Acad. Sci. USA 78:3824-3828 (1981).
Kalyanaraman et al., Science 225:321-323 (1984).
Kennedy et al, "Antiserum to a Synthetic Peptide Recognizes the HTLV-III Envelope GLoycoprotein" Science 231 (Mar. 28, 1986) 1556-1559.* *
Kitchen et al., Nature 312:367-389 (1984).
Lange et al, "Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus" Br. J. Cancer 292 (Jan. 25, 1986) 228-230.* *
Mortimer et al "Which anti-HTLV-III/LAV assays for screening and confirmatory testing?" Lancet Oct. 19, 1985 873-877.* *
Muesing et al, "Nucleic acid structure and expression of the human AIDS/lymphadeno-pathy retovirus" Nature 313 (Feb. 7, 1985) 450-458.* *
Pauletti et al., Anal. Biochem. 151:540-546 (1985).
Ratner et al., Nature 313:277-284 (1985).
Robey et al., Science 228:593-595 (1985).
Sanchez-Pescador et al., Science 227:484-492 (1985).
Schüpbach et al, "Antibodies to HTLV-III in Swiss Patients with AIDS and Pre-AIDS and in Groups at Risk for AIDS" N.E. J Med 312 (Jan. 31, 1985) 265-270.* *
Schupbach et al., Science 224:503-505 (1984).
Shaw et al., Science 226:1165-1171 (1984).
Tainer et al., Nature 312:127-134 (1984).
Veronese et al., Science 229:1402-1405 (1985).
Wain-Hobson et al., Cell 40:90-17 (1985).
Wilson et al., Proc. Natl. Acad. Sci. 82:5255-5259 (1987).* *

Also Published As

Publication number Publication date
US6214539B1 (en) 2001-04-10
ATE116006T1 (en) 1995-01-15
KR880700080A (en) 1988-02-15
DK84195A (en) 1995-07-18
DK171250B1 (en) 1996-08-12
DE3650175T2 (en) 1995-06-14
EP0220273B1 (en) 1994-12-21
AU597884B2 (en) 1990-06-14
FI865313A (en) 1986-12-29
DK626486A (en) 1986-12-23
FI91073C (en) 1994-05-10
WO1986006414A1 (en) 1986-11-06
EP0220273A1 (en) 1987-05-06
DK626486D0 (en) 1986-12-23
DE3650175D1 (en) 1995-02-02
AU5773386A (en) 1986-11-18
EP0220273A4 (en) 1989-10-04
FI865313A0 (en) 1986-12-29
DE3650175T3 (en) 2007-09-06
FI91073B (en) 1994-01-31
EP0220273B2 (en) 2007-01-17
KR910002374B1 (en) 1991-04-20

Similar Documents

Publication Publication Date Title
US6485900B1 (en) Synthetic antigen for the detection of AIDS-related disease
US4629783A (en) Synthetic antigen for the detection of AIDS-related disease
US5075211A (en) Synthetic antigen for the detection of AIDS-related disease
US20030215788A1 (en) Cysteine thiol-protected peptides for use in immunoassays
EP0247557A2 (en) HTLV-III(LAV) Envelope peptides
US6322964B1 (en) Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies
EP0326490B2 (en) Synthetic peptides and mixtures thereof for detecting HIV antibodies
EP0284383B1 (en) Synthetic antigens for the detection of aids-related disease caused by LAV-2
US7144697B1 (en) Synthetic antigen for the detection of antibodies immunoreactive with HIV virus
US6130314A (en) Synthetic antigen for the detection of AIDS-related disease
AU597884C (en) Synthetic antigens for the detection of AIDS-related disease
NO304151B1 (en) Oxidized peptide which is immunoreactive with antibodies to a natural retrovirus protein, method of preparing and using a peptide-coated solid phase
JP2705791B2 (en) Synthetic antigens for detection of AIDS-related diseases
US6210874B1 (en) Synthetic peptides and mixtures thereof for detecting HIV antibodies
NO173034B (en) PROCEDURES AND PEPTIDES FOR DETECTION OF AIDS-RELATED DISEASE

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12